PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
 
Infect Immun. 1995 July; 63(7): 2403–2408.
PMCID: PMC173321

Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis.

Abstract

The etiology of recurrent vulvovaginal candidiasis in otherwise healthy women of child-bearing age remains an enigma. To date, results from both clinical studies and a murine model of vaginal candidiasis indicate that Candida vaginitis can occur in the presence of Candida-specific Th1-type cell-mediated immunity expressed in the peripheral circulation. The present study was designed to determine the role of circulating CD4 and CD8 cells in primary and secondary vaginal infections with Candida albicans. Vaginal fungal burden, Candida-specific delayed-type hypersensitivity (DTH), and lymph node cell Th1/Th2 cytokine production were monitored in CD4 and/or CD8 cell-depleted mice during persistent primary vaginal infections and secondary vaginal infections against which partial protection was observed. Treatment of mice with anti-CD4 or anti-CD8 antibodies resulted in 90% or greater depletion of the respective cell populations. Mice depleted of CD4 cells had significantly reduced Candida-specific DTH and lymph node cell Th1-type cytokine production during a primary vaginal infection, as well as reduced anamnestic DTH during a secondary vaginal infection. In contrast, mice depleted of CD8 cells showed only reduced gamma interferon production during a primary infection; no alterations in DTH were observed. Despite reductions in DTH and cytokine production, however, CD4 and/or CD8 cell depletion had no effect on vaginal C. albicans burden in mice after a primary or secondary vaginal inoculation. Taken together, these results suggest that while circulating CD4 and CD8 cells contribute to systemic Candida-specific cell-mediated immunity in vaginally infected mice, neither CD4 nor CD8 circulating T cells appear to provide significant host defenses against C. albicans at the vaginal mucosa.

Full Text

The Full Text of this article is available as a PDF (208K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Chace JH, Cowdery JS, Field EH. Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J Immunol. 1994 Jan 15;152(2):405–412. [PubMed]
  • Clift RA. Candidiasis in the transplant patient. Am J Med. 1984 Oct 30;77(4D):34–38. [PubMed]
  • Domer JE, Garner RE, Befidi-Mengue RN. Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI. Infect Immun. 1989 Mar;57(3):693–700. [PMC free article] [PubMed]
  • Fidel PL, Jr, Lynch ME, Conaway DH, Tait L, Sobel JD. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun. 1995 Feb;63(2):547–553. [PMC free article] [PubMed]
  • Fidel PL, Jr, Lynch ME, Sobel JD. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun. 1993 May;61(5):1990–1995. [PMC free article] [PubMed]
  • Fidel PL, Jr, Lynch ME, Sobel JD. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun. 1993 Oct;61(10):4202–4207. [PMC free article] [PubMed]
  • Fidel PL, Jr, Lynch ME, Sobel JD. Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun. 1994 Mar;62(3):1032–1038. [PMC free article] [PubMed]
  • Fidel PL, Jr, Lynch ME, Redondo-Lopez V, Sobel JD, Robinson R. Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis. J Infect Dis. 1993 Dec;168(6):1458–1465. [PubMed]
  • Fong IW, McCleary P, Read S. Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis. Am J Obstet Gynecol. 1992 Mar;166(3):887–890. [PubMed]
  • Garner RE, Domer JE. Lack of effect of Candida albicans mannan on development of protective immune responses in experimental murine candidiasis. Infect Immun. 1994 Feb;62(2):738–741. [PMC free article] [PubMed]
  • Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed]
  • Hersh EV, Gutterman JU, Mavligit GM. Effect of haematological malignancies and their treatment on host defence factors. Clin Haematol. 1976 Jun;5(2):425–448. [PubMed]
  • Hobbs JR, Brigden D, Davidson F, Kahan M, Oates JK. Immunological aspects of candidal vaginitis. Proc R Soc Med. 1977;70 (Suppl 4):11–14. [PMC free article] [PubMed]
  • Hu-Li J, Ohara J, Watson C, Tsang W, Paul WE. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol. 1989 Feb 1;142(3):800–807. [PubMed]
  • Hurley R. Candidal vaginitis. Proc R Soc Med. 1977;70 (Suppl 4):1–2. [PMC free article] [PubMed]
  • Hurley R. Recurrent Candida infection. Clin Obstet Gynaecol. 1981 Apr;8(1):209–214. [PubMed]
  • Hurley R, De Louvois J. Candida vaginitis. Postgrad Med J. 1979 Sep;55(647):645–647. [PMC free article] [PubMed]
  • Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984 Aug 9;311(6):354–358. [PubMed]
  • Knight L, Fletcher J. Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus. J Infect Dis. 1971 Apr;123(4):371–377. [PubMed]
  • Macher AM. The pathology of AIDS. Public Health Rep. 1988 May-Jun;103(3):246–254. [PMC free article] [PubMed]
  • Nandi D, Allison JP. Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J Immunol. 1991 Sep 15;147(6):1773–1778. [PubMed]
  • Polonelli L, De Bernardis F, Conti S, Boccanera M, Gerloni M, Morace G, Magliani W, Chezzi C, Cassone A. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol. 1994 Mar 15;152(6):3175–3182. [PubMed]
  • Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci. 1988;544:547–557. [PubMed]
  • Syverson RE, Buckley H, Gibian J, Ryan GM., Jr Cellular and humoral immune status in women with chronic Candida vaginitis. Am J Obstet Gynecol. 1979 Jul 15;134(6):624–627. [PubMed]
  • Witkin SS. Inhibition of Candida-induced lymphocyte proliferation by antibody to Candida albicans. Obstet Gynecol. 1986 Nov;68(5):696–699. [PubMed]
  • Witkin SS, Hirsch J, Ledger WJ. A macrophage defect in women with recurrent Candida vaginitis and its reversal in vitro by prostaglandin inhibitors. Am J Obstet Gynecol. 1986 Oct;155(4):790–795. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)